Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Gerger, A; Labonte, M; Lenz, HJ.
Molecular predictors of response to antiangiogenesis therapies.
Cancer J. 2011; 17(2):134-141
Doi: 10.1097/PPO.0b013e318212db3c
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Gerger Armin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Angiogenesis is a crucial component of tumor growth and metastasis. Targeting the vascular endothelial growth factor pathway represents therapeutic potentials for treating cancer. To date, 3 Food and Drug Administration-approved agents targeting angiogenesis have been developed, bevacizumab, sunitinib, and sorafenib. However, no validated biomarkers are available to identify those patients who are likely to benefit from antiangiogenesis therapy. Molecular biomarker research in antiangiogenesis inhibition is an actively growing field. Although current data are extremely promising, it is still uncertain which biomarker(s) can reliably predict their efficacy. With increasing numbers of inhibitors being developed, the need for biomarkers is more critical than ever. This review will focus on translational research that strives to identify molecular biomarkers (tissue, circulating and genomic) for approved antiangiogenesis therapies that can indicate benefit, resistance, and toxicity.
- Find related publications in this database (using NLM MeSH Indexing)
- Angiogenesis Inhibitors - therapeutic use
- Humans -
- Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - genetics
- Signal Transduction -
- Treatment Outcome -
- Tumor Markers, Biological - genetics Tumor Markers, Biological - metabolism
- Vascular Endothelial Growth Factor A - genetics Vascular Endothelial Growth Factor A - metabolism
- Find related publications in this database (Keywords)
- Angiogenesis
- VEGF
- biomarker